Telo Genomics pioneers the most comprehensive 3-dimensional telomere analytics platform to assess risk of progression, treatment outcome or active monitoring of multiple myeloma patients and other cancers. TeloView®, the company’s ground-breaking single-cell analysis platform, utilizes a proprietary algorithm to quantify genomic disease signals enabling dynamic assessment of genomic changes and empowering precision medicine treatment decisions. TeloView technology is applicable to liquid biopsy.
Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers.Our lead application is being developed to provide important, actionable information for the treatment of Multiple Myeloma, a deadly form of blood cancer.